E
SAGE

Ergoteles’s Sage Therapeutics SAGE Stock Holding History

Ergoteles’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,309
Closed -$1.66M – 686
2023
Q2 		$1.66M Buy
35,309
+8,440
+31% +$420K 0.08% 321
2023
Q1 		$1.13M Sell
26,869
-23,198
-46% -$997K 0.04% 448
2022
Q4 		$1.91M Buy
+50,067
New +$1.91M 0.07% 293
2022
Q1 		– Sell
-19,195
Closed -$817K – 1587
2021
Q4 		$817K Buy
19,195
+6,634
+53% +$278K 0.03% 482
2021
Q3 		$557K Sell
12,561
-70,372
-85% -$3.23M 0.02% 540
2021
Q2 		$4.71M Buy
82,933
+63,330
+323% +$4.48M 0.11% 232
2021
Q1 		$1.47M Buy
19,603
+12,793
+188% +$1.05M 0.05% 322
2020
Q4 		$589K Sell
6,810
-62,974
-90% -$4.64M 0.02% 428
2020
Q3 		$4.26M Buy
+69,784
New +$3.54M 0.56% 31

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ergoteles's SAGE Position: Q3 2023 in Review

Ergoteles sold out of Sage Therapeutics (SAGE) in Q3 2023, closing a stake of 35,309 shares — an estimated $1.66M sold.

Ergoteles first reported a position in SAGE in Q3 2020 and held it in 9 quarters. The position peaked at $4.71M in Q2 2021. 194 funds tracked by Wall St. Rank hold SAGE as of Q3 2023.

  • Ergoteles reported no remaining Sage Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 35,309 Sage Therapeutics shares in Q3 2023, an estimated $1.66M.
  • Ergoteles first reported a position in Sage Therapeutics in Q3 2020 and held it in 9 quarters.
  • Ergoteles's Sage Therapeutics position peaked at $4.71M in Q2 2021.
  • 194 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.